OBJECTIVES: Although dramatic improvements of overall survival has achieved in patients with favourable histology Wilms tumour, disease recurrence is still the main cause of cancer-related death in childhood. Long non-coding RNAs (lncRNAs) as oncogenes or tumour suppressors are dysregulated during carcinogenesis. However, the role of lncRNAs in the pathogenesis of Wilms tumour is unknown. Here, an lncRNA LINC00473 signature that functioned as oncogene was identified in Wilms tumour. METHODS: Wilms tumour (n = 15) and relative normal tissues were collected. The LINC00473 expression and function in Wilms tumour was determined. The LncRNA-miRNA network of LINC00473 was analysed in vitro and vivo. RESULTS: We uncovered that the expression of LINC00473 was elevated in tumour tissues than that in relative normal tissues. Higher LINC00473 levels correlated to higher stage and unfavourable histology Wilms tumour. Mechanistically, knockdown of LINC00473 inhibited cell vitality and induced Bcl-2-dependent apoptosis and G1/S arrest via CDK2 and cyclin D1. Moreover, LINC00473 harboured binding sites for miR-195 and limited miR-195 availability in a dose-dependent manner. Forced expression of miR-195 impaired tumour survival and metastasis, which, however, could be restored by LINC00473. Furthermore, IKKα was the downstream of LINC00473/miR-195 signals and could be directly targeted by miR-195 to participate LINC00473-induced tumour progression. Loss-of-function of LINC00473 in vivo effectively promoted the regression of Wilms tumour via miR-195/IKKα-mediated growth inhibition. CONCLUSION: LINC00473 as an oncogene is up-regulated to participate into the molecular pathogenesis of Wilms tumour via miR-195/IKKα.
OBJECTIVES: Although dramatic improvements of overall survival has achieved in patients with favourable histology Wilms tumour, disease recurrence is still the main cause of cancer-related death in childhood. Long non-coding RNAs (lncRNAs) as oncogenes or tumour suppressors are dysregulated during carcinogenesis. However, the role of lncRNAs in the pathogenesis of Wilms tumour is unknown. Here, an lncRNA LINC00473 signature that functioned as oncogene was identified in Wilms tumour. METHODS:Wilms tumour (n = 15) and relative normal tissues were collected. The LINC00473 expression and function in Wilms tumour was determined. The LncRNA-miRNA network of LINC00473 was analysed in vitro and vivo. RESULTS: We uncovered that the expression of LINC00473 was elevated in tumour tissues than that in relative normal tissues. Higher LINC00473 levels correlated to higher stage and unfavourable histology Wilms tumour. Mechanistically, knockdown of LINC00473 inhibited cell vitality and induced Bcl-2-dependent apoptosis and G1/S arrest via CDK2 and cyclin D1. Moreover, LINC00473 harboured binding sites for miR-195 and limited miR-195 availability in a dose-dependent manner. Forced expression of miR-195impaired tumour survival and metastasis, which, however, could be restored by LINC00473. Furthermore, IKKα was the downstream of LINC00473/miR-195 signals and could be directly targeted by miR-195 to participate LINC00473-induced tumour progression. Loss-of-function of LINC00473 in vivo effectively promoted the regression of Wilms tumour via miR-195/IKKα-mediated growth inhibition. CONCLUSION:LINC00473 as an oncogene is up-regulated to participate into the molecular pathogenesis of Wilms tumour via miR-195/IKKα.
Authors: Karin Koller; Martin Pichler; Karin Koch; Martina Zandl; Verena Stiegelbauer; Ivo Leuschner; Gerald Hoefler; Barbara Guertl Journal: Pediatr Dev Pathol Date: 2014-03-11
Authors: Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Zirong Chen; Jian-Liang Li; Shuibin Lin; Chunxia Cao; Nicholas T Gimbrone; Rongqiang Yang; Dongtao A Fu; Miranda B Carper; Eric B Haura; Matthew B Schabath; Jianrong Lu; Antonio L Amelio; W Douglas Cress; Frederic J Kaye; Lizi Wu Journal: J Clin Invest Date: 2016-05-03 Impact factor: 14.808
Authors: Josefa P Alameda; Manuel Navarro; Ángel Ramírez; Angustias Page; Cristian Suárez-Cabrera; Rodolfo Moreno-Maldonado; Jesús M Paramio; María del Carmen Fariña; Marcela Del Río; María Jesús Fernández-Aceñero; Ana Bravo; María de Los Llanos Casanova Journal: Oncotarget Date: 2016-11-22
Authors: Orna Issler; Yentl Y van der Zee; Aarthi Ramakrishnan; Junshi Wang; Chunfeng Tan; Yong-Hwee E Loh; Immanuel Purushothaman; Deena M Walker; Zachary S Lorsch; Peter J Hamilton; Catherine J Peña; Erin Flaherty; Brigham J Hartley; Angélica Torres-Berrío; Eric M Parise; Hope Kronman; Julia E Duffy; Molly S Estill; Erin S Calipari; Benoit Labonté; Rachael L Neve; Carol A Tamminga; Kristen J Brennand; Yan Dong; Li Shen; Eric J Nestler Journal: Neuron Date: 2020-04-17 Impact factor: 17.173